Skip to main content

Cardiogenic Shock

3
Pipeline Programs
10
Companies
13
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
2
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 12 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
3 programs
1
LevosimendanPhase 2/31 trial
HeartMate PHPN/A1 trial
VasopressorN/A1 trial
Active Trials
NCT02279979Terminated9Est. Jan 2017
NCT04682483Recruiting5,000Est. Jun 2026
NCT00093301Unknown40Est. Apr 2006
Eppendorf
EppendorfGermany - Hamburg
3 programs
1
AdrecizumabPhase 2/3Monoclonal Antibody1 trial
ImpellaN/A1 trial
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCKN/A1 trial
Active Trials
NCT05577195Unknown198Est. Dec 2025
NCT03313687Recruiting2,500Est. Dec 2031
NCT03989531Completed150Est. Apr 2021
4TEEN4 Pharmaceuticals
4TEEN4 PharmaceuticalsGermany - Hennigsdorf
1 program
1
procizumabPhase 1/2Monoclonal Antibody2 trials
Active Trials
NCT06832722Recruiting130Est. Dec 2026
NCT06331884Completed24Est. Sep 2024
iNova Pharmaceuticals
iNova PharmaceuticalsAustralia - Chatswood
1 program
Cardiogenic Shock team activationN/A1 trial
Active Trials
NCT03378739Recruiting3,000Est. Dec 2099
Magenta Medical
Magenta MedicalIsrael - Kadima
1 program
Elevate™ SystemN/A1 trial
Active Trials
NCT07293923Recruiting10Est. Oct 2026
Zoll
ZollCA - San Jose
1 program
IVTM™ SystemN/A1 trial
Active Trials
NCT03141255Completed20Est. Nov 2021
Teleflex Medical
Teleflex MedicalAustralia - Mascot
1 program
Intra-Aortic Balloon PumpN/A1 trial
Active Trials
NCT06414187Not Yet Recruiting400Est. Jun 2027
Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
National Cardiogenic Shock InitiativeN/A1 trial
Active Trials
NCT03677180Completed406Est. Dec 2020
Boston Scientific
Boston ScientificCA - Valencia
1 program
VasopressorN/A
Getinge
GetingeChina - Suzhou
1 program
VasopressorN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
EppendorfAdrecizumab
AbbottLevosimendan
4TEEN4 Pharmaceuticalsprocizumab
4TEEN4 Pharmaceuticalsprocizumab
Magenta MedicalElevate™ System
Teleflex MedicalIntra-Aortic Balloon Pump
EppendorfImpella
iNova PharmaceuticalsCardiogenic Shock team activation
AbbottVasopressor
ZollIVTM™ System
EppendorfSafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
ChiesiNational Cardiogenic Shock Initiative
AbbottHeartMate PHP

Clinical Trials (13)

Total enrollment: 11,887 patients across 13 trials

NCT03989531EppendorfAdrecizumab

Adrecizumab in Cardiogenic Shock

Start: Apr 2019Est. completion: Apr 2021150 patients
Phase 2/3Completed
NCT00093301AbbottLevosimendan

Levosimendan Versus Dobutamine in Shock Patients

Start: Oct 2004Est. completion: Apr 200640 patients
Phase 2/3Unknown
NCT068327224TEEN4 Pharmaceuticalsprocizumab

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Start: Jul 2025Est. completion: Dec 2026130 patients
Phase 1/2Recruiting
NCT063318844TEEN4 Pharmaceuticalsprocizumab

Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

Start: Mar 2024Est. completion: Sep 202424 patients
Phase 1Completed
NCT07293923Magenta MedicalElevate™ System

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

Start: Nov 2025Est. completion: Oct 202610 patients
N/ARecruiting
NCT06414187Teleflex MedicalIntra-Aortic Balloon Pump

Clinical Effects of Intra-aortic Balloon Support in Early Acute Coronary Syndrome and Non-Acute Coronary Syndrome Related Cardiogenic Shock

Start: Jun 2024Est. completion: Jun 2027400 patients
N/ANot Yet Recruiting
NCT05577195EppendorfImpella

Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO

Start: Nov 2022Est. completion: Dec 2025198 patients
N/AUnknown
NCT03378739iNova PharmaceuticalsCardiogenic Shock team activation

Inova Cardiogenic Shock Registry (INOVA SHOCK)

Start: Jan 2018Est. completion: Dec 20993,000 patients
N/ARecruiting
NCT04682483AbbottVasopressor

Cardiogenic Shock Working Group Registry

Start: Dec 2017Est. completion: Jun 20265,000 patients
N/ARecruiting
NCT03141255ZollIVTM™ System

Cardiogenic Shock Intravascular Cooling Trial

Start: Nov 2017Est. completion: Nov 202120 patients
N/ACompleted
NCT03313687EppendorfSafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK

SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK

Start: Sep 2017Est. completion: Dec 20312,500 patients
N/ARecruiting
NCT03677180ChiesiNational Cardiogenic Shock Initiative

National Cardiogenic Shock Initiative

Start: May 2016Est. completion: Dec 2020406 patients
N/ACompleted
NCT02279979AbbottHeartMate PHP

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Start: Oct 2014Est. completion: Jan 20179 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 actively recruiting trials targeting 11,887 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.